Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in São Paulo, Brazil

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 2122-2125

  Mantovani, N P ^a   Azevedo, R G ^a   Rabelato, J T ^b   Sanabani, S ^c   Diaz, R S ^a   Komninakis, S V ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Lusiada Foundation of Santos   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; INTEGRASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

AMINO TERMINAL SEQUENCE; ARTICLE; BRAZIL; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PHYLOGENY; PRIORITY JOURNAL; RNA EXTRACTION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMORPHISM, GENETIC; PYRROLIDINONES; SELECTION, GENETIC; SEQUENCE HOMOLOGY, AMINO ACID; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84862101063     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00539-12     Document Type: Article

References (12)

1. Arruda LB, Fonseca LA, Duarte AJ, Casseb J. 2010. Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in Sao Paulo City, Brazil. AIDS Res. Hum. Retroviruses 26:105-107.
2. Canducci F, et al. 2010. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J. Antimicrob. Chemother. 65:425-433.
3. Ceccherini-Silberstein F, et al. 2010. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J. Antimicrob. Chemother. 65:2305-2318.
4. Fransen S, et al. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446.
5. Garrido C, et al. 2010. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J. Antimicrob. Chemother. 65:320-326.
6. Gräf T, et al. 2011. HIV-1 genetic diversity and drug resistance among treatment naive patients from Southern Brazil: an association of HIV-1 subtypes with exposure categories. J. Clin. Virol. 51:186-191.
7. Low A, et al. 2009. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob. Agents Chemother. 53:4275-4282.
8. Nei M, Kumar S. 2000. Molecular evolution and phylogenetics. Oxford University Press, New York, NY.
9. Passaes CB, et al. 2009. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J. Acquir. Immune Defic. Syndr. 51:7-12.
10. Shafer RW, Schapiro JM. 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10: 67-84.
11. Sichtig N, et al. 2009. Evolution of raltegravir resistance during therapy. J. Antimicrob. Chemother. 64:25-32.
12. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-4882. (Pubitemid 28022245)